JP Morgan Chase
BLCM

JP Morgan Chase’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

JP Morgan Chase’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1
Closed – – 7511
2023
Q1 		$0 Hold
1
– – ﹤0.01% 7433
2022
Q4 		$0 Buy
+1
New +$1 ﹤0.01% 7222
2019
Q4 		– Sell
-27,216
Closed -$286K – 5969
2019
Q3 		$286K Sell
27,216
-310,899
-92% -$4.06M ﹤0.01% 4458
2019
Q2 		$6.73M Sell
338,115
-80,887
-19% -$2.19M ﹤0.01% 2411
2019
Q1 		$14.1M Buy
419,002
+19,423
+5% +$649K ﹤0.01% 1785
2018
Q4 		$11.7M Buy
399,579
+12,139
+3% +$539K ﹤0.01% 1886
2018
Q3 		$23.9M Buy
387,440
+30,082
+8% +$2.04M ﹤0.01% 1524
2018
Q2 		$26.4M Buy
357,358
+71,054
+25% +$5.54M 0.01% 1380
2018
Q1 		$18.8M Buy
286,304
+52,397
+22% +$3.96M ﹤0.01% 1554
2017
Q4 		$19.7M Buy
233,907
+7,596
+3% +$745K ﹤0.01% 1584
2017
Q3 		$26.2M Sell
226,311
-20,364
-8% -$2.14M 0.01% 1318
2017
Q2 		$28.8M Buy
246,675
+22,767
+10% +$2.83M 0.01% 1214
2017
Q1 		$27.6M Buy
223,908
+11,448
+5% +$1.5M 0.01% 1258
2016
Q4 		$28.9M Sell
212,460
-10,946
-5% -$1.94M 0.01% 1225
2016
Q3 		$44.5M Sell
223,406
-12,133
-5% -$2.09M 0.01% 887
2016
Q2 		$30.5M Sell
235,539
-8,278
-3% -$921K 0.01% 1113
2016
Q1 		$22.8M Buy
243,817
+61,688
+34% +$6.72M 0.01% 1254
2015
Q4 		$36.9M Buy
182,129
+62,962
+53% +$11.3M 0.01% 964
2015
Q3 		$17.3M Buy
119,167
+26,731
+29% +$4.91M ﹤0.01% 1361
2015
Q2 		$19.7M Buy
92,436
+5,966
+7% +$1.46M ﹤0.01% 1416
2015
Q1 		$20M Buy
86,470
+36,713
+74% +$8.88M ﹤0.01% 1431
2014
Q4 		$11.5M Buy
+49,757
New +$10.7M ﹤0.01% 1855

Other funds holding BLCM

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
PGAM
Princeton Global Asset Management Princeton, New Jersey $698M AUM 31.09% 1-Year Est. Return

JP Morgan Chase's BLCM Position: Q2 2023 in Review

JP Morgan Chase sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2023, closing a stake of 1 share.

JP Morgan Chase first reported a position in BLCM in Q4 2014 and held it in 22 quarters. The position peaked at $44.5M in Q3 2016. 4 funds tracked by Wall St. Rank hold BLCM as of Q2 2023.

  • JP Morgan Chase reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • JP Morgan Chase sold 1 Bellicum Pharmaceuticals, Inc. share in Q2 2023.
  • JP Morgan Chase first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 22 quarters.
  • JP Morgan Chase's Bellicum Pharmaceuticals, Inc. position peaked at $44.5M in Q3 2016.
  • 4 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2023.

Based on JP Morgan Chase's 13F filing for Q2 2023, filed 11 Aug 2023.